Vascular endothelial growth factor expression in serous ovarian carcinoma: Relationship with topoisomerase IIα and prognosis

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 16-22

  Brustmann, Hermann ^a  

^a Austria ^*  (Austria)

Author keywords

Grade; Outcome; Prognosis; Serous ovarian carcinoma; Stage; Topoisomerase II ; Vascular endothelial growth factor (VEGF)

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); TOPOISOMERASE II ALPHA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYSTADENOMA; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SECTION; TUMOR CELL;

EID: 4644359804     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.040     Document Type: Article

References (29)

1. R.E. Scully, R.H. Young, and P.B. Clement Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament Atlas of Tumor Pathology 1996 Armed Forces Institute of Pathology Washington, DC
2. N. Ferrara, and T. Davis-Smyth The biology of vascular endothelial growth factor Endocr. Rev. 18 1997 4 25
3. C.A. Boocock, S. Charnock-Jones, A.M. Sharkey, J. McLaren, P.J. Baker, and K.A. Wright Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma J. Natl. Cancer Inst. 87 1995 506 516
4. H. Brustmann, and S. Naude Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage Gynecol. Oncol. 84 2002 47 52
5. J. Mu, Y. Abe, T. Tsutsui, N. Yamamoto, X.G. Tai, and O. Niwa Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity Jpn. J. Cancer Res. 87 1996 963 971
6. M.J. Costa, C.L. Hansen, J.A. Holden, and D. Guinee Topoisomerase IIα: prognostic and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum Int. J. Gynecol. Pathol. 19 2000 248 257
7. J.G. Hengstler, J. Lange, A. Kett, N. Dornhofer, R. Meinert, and M. Arand Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer Cancer Res. 59 1999 3206 3214
8. S. Withoff, A.G.J. van der Zee, S. de Jong, H. Hollema, E.F. Smit, and N.H. Mulder DNA topoisomerase IIα and -β expression in human ovarian cancer Br. J. Cancer 79 1999 748 753
9. Y. Shimizu, S. Kamoi, S. Amada, F. Akiyama, and S.G. Silverberg Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up Cancer 82 1998 893 901
10. B.R. Kamat, L.F. Brown, E.J. Manseau, D.R. Senger, and H.F. Dvorak Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells Am. J. Pathol. 146 1995 157 165
11. G.G. Garzetti, A. Ciavattini, G. Lucarini, A. Pugnaloni, M. De Nictolis, and S. Amati Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystadenocarcinomas: relationship with MIB 1 immunostaining Gynecol. Oncol. 73 1999 396 401 (ID gyno. 1999.5377)
12. G.G. Garzetti, A. Ciavattini, G. Goteri, M. De Nicoltis, D. Stramazzotti, and G. Lucarini Ki 67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity, with prognostic significance Gynecol. Oncol. 56 1995 169 174
13. P.J. Paley, K.A. Staskus, K. Gebhard, D. Mohanraj, L.B. Twiggs, and L.F. Carson Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 80 1997 98 106
14. J. Mattern, G. Stammler, R. Koomagi, D. Wallwiener, M. Kaufmann, and M. Volm Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma Anticancer Res. 17 1997 621 624
15. L. Nakopoulou, K. Stefanaki, E. Panayotopoulou, I. Giannopoulou, P. Athanassiadou, and P. Gakiopoulou-Givalou Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation Hum. Pathol. 33 2002 863 870
16. B.J. Lynch, D.G. Guinee, and J.A. Holden Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer Hum. Pathol. 28 1997 1180 1188
17. E.M. Hartenbach, T.A. Olson, J.J. Goswitz, D. Mohanraj, L.B. Twiggs, and L.F. Carson Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas Cancer Lett. 121 1997 169 175
18. G.H. Shen, M. Ghazizadeh, O. Kawanami, H. Shimizu, E. Jin, and T. Araki Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma Br. J. Cancer 83 2000 196 203
19. C.A. Chen, W.F. Cheng, C.N. Lee, T.M. Chen, C.C. Kung, and F.J. Hsieh Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival Gynecol. Oncol. 74 1999 235 240
20. Y. Yokoyama, D.S. Charnock-Jones, D. Licence, A. Yanaihara, J.M. Hastings, and C.M. Holland Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma Br. J. Cancer 88 2003 237 244
21. H. Brustmann Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study Gynecol. Oncol. 92 2004 268 276
22. M. Coronarotti, G. Capranico, S. Bohm, S. Orlana, G.B. Spatti, and L. Mariani Gene expression of DNA topoisomerase I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma Int. J. Cancer 67 1996 479 484
23. M. Koshiyama, H. Fuji, M. Kinezaki, and M. Yoshida Correlation between topo IIα expression and chemosensitivity testing for topo II-targeting drugs in gynaecological carcinomas Anticancer Res. 21 2001 905 910
24. J.P. Eder Jr., V.T. Chan, S.W. Ng, N.A. Rizvi, S. Zacharoulis, B.A. Teicher, and L.E. Schnipper DNA topoisomerase II alpha is associated with alkylating agent resistance Cancer Res. 55 1995 6109 6116
25. F. Ali-Osman, M.S. Berger, S. Rajagopal, A. Spence, and R.B. Livingstóne Topoisomerase inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells Cancer Res. 53 1993 5663 5668
26. T. Stevnsner, and V.A. Bohr Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair Carcinogenesis 14 1993 1841 1850
27. L. Hu, J. Hofmann, C. Zaloudek, N. Ferrara, T. Hamilton, and R.B. Jaffe Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer Am. J. Pathol. 161 2002 1917 1924
28. F. Ciadiello, R. Caputom, V. Damiano, R. Caputo, T. Troiani, and D. Vitagliano Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin. Cancer Res. 9 2003 1546 1556
29. R.A. Spooner, F. Friedlos, K. Maycroft, S.M. Stribbling, J. Roussel, and J. Brueggen A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs Br. J. Cancer 88 2003 1622 1630